Akebia Therapeutics (AKBA) Aperçu de l'action
Akebia Therapeutics, Inc. est une société biopharmaceutique qui se concentre sur le développement et la commercialisation de produits thérapeutiques pour les patients souffrant de maladies rénales. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
AKBA Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$77.29
FV
98.6% sous-évalué décote intrinsèque271
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
Akebia Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.07 |
| Plus haut sur 52 semaines | US$4.08 |
| Plus bas sur 52 semaines | US$0.82 |
| Bêta | 0.25 |
| Variation sur 1 mois | 19.54% |
| Variation sur 3 mois | -24.65% |
| Variation sur 1 an | -69.94% |
| Variation sur 3 ans | 1.90% |
| Variation sur 5 ans | -74.40% |
| Évolution depuis l'introduction en bourse | -95.99% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 05
AKBA: Kidney Pipeline Expansion And Share Authorization Increase Will Support Upside Potential
Analysts have maintained their $6.00 price target for Akebia Therapeutics, citing only minor updates in their underlying assumptions on discount rate, revenue growth, profit margins, and future P/E as the reason for no change in the headline number. What's in the News Akebia Therapeutics plans to seek shareholder approval to amend its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock to 525,000,000 shares and authorized common stock to 500,000,000 shares.Mise à jour du récit • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Article d’analyse • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Recent updates
Mise à jour du récit • Jun 05
AKBA: Kidney Pipeline Expansion And Share Authorization Increase Will Support Upside Potential
Analysts have maintained their $6.00 price target for Akebia Therapeutics, citing only minor updates in their underlying assumptions on discount rate, revenue growth, profit margins, and future P/E as the reason for no change in the headline number. What's in the News Akebia Therapeutics plans to seek shareholder approval to amend its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock to 525,000,000 shares and authorized common stock to 500,000,000 shares.Mise à jour du récit • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Article d’analyse • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Mise à jour du récit • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.
Mise à jour du récit • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Mise à jour du récit • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Mise à jour du récit • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.
Nouveau récit • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Mise à jour du récit • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Mise à jour du récit • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Mise à jour du récit • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Mise à jour du récit • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Mise à jour du récit • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Mise à jour du récit • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Mise à jour du récit • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Mise à jour du récit • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Mise à jour du récit • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Article d’analyse • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Mise à jour du récit • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Article d’analyse • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Article d’analyse • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Article d’analyse • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Article d’analyse • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
Nouveau récit • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Article d’analyse • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Article d’analyse • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Article d’analyse • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Article d’analyse • Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Article d’analyse • Aug 02
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders are no doubt pleased to see that the share price has bounced 34...Rendement pour les actionnaires
| AKBA | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 19.0% | 4.6% | 2.0% |
| 1Y | -69.9% | 30.5% | 23.3% |
Rendement vs Industrie: AKBA a sous-performé le secteur US Biotechs qui a rapporté 30.5 % au cours de l'année écoulée.
Rendement vs marché: AKBA a sous-performé le marché US qui a rapporté 23.3 % au cours de l'année écoulée.
Volatilité des prix
| AKBA volatility | |
|---|---|
| AKBA Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: AKBA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de AKBA ( 11% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2007 | 194 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc. est une société biopharmaceutique qui se concentre sur le développement et la commercialisation de produits thérapeutiques pour les patients souffrant de maladies rénales. Son portefeuille de produits comprend Vafseo (vadadustat), une prolyl hydroxylase du facteur inductible à l'hypoxie administrée par voie orale, pour le traitement de l'anémie due à l'insuffisance rénale chronique (IRC) chez les patients dépendants de la dialyse (DD) et non dépendants de la dialyse (NDD) ; et Auryxia, un citrate ferrique utilisé pour contrôler les niveaux de phosphore sérique chez les patients adultes atteints d'IRC-DD et pour le traitement de l'anémie ferriprive chez les patients adultes atteints d'IRC-NDD. La société développe également l'AKB-9090, qui est en essai clinique de phase 2 pour le traitement des lésions rénales aiguës liées à la chirurgie cardiaque et du syndrome de détresse respiratoire aiguë, ainsi que l'AKB-10108 pour le traitement de la rétinopathie de la prématurité chez les nouveau-nés.
Akebia Therapeutics, Inc. Résumé des fondamentaux
| AKBA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$273.62m |
| Bénéfices(TTM) | -US$20.51m |
| Recettes(TTM) | US$232.40m |
1.2x
Ratio P/S-14.0x
Ratio P/ELe site AKBA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| AKBA compte de résultat (TTM) | |
|---|---|
| Recettes | US$232.40m |
| Coût des recettes | US$41.97m |
| Marge brute | US$190.43m |
| Autres dépenses | US$210.94m |
| Les revenus | -US$20.51m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.076 |
| Marge brute | 81.94% |
| Marge bénéficiaire nette | -8.83% |
| Ratio dettes/capitaux propres | 713.8% |
Quelles ont été les performances à long terme de AKBA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/18 23:17 |
| Cours de l'action en fin de journée | 2026/06/18 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Akebia Therapeutics, Inc. est couverte par 17 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |